

Instant Claims

PU3616US2

In the Claims:

Please cancel claims 1-11, 14, 17-19 and 22-35 without prejudice thereto. Please amend the claims as follows:

Claims 1 - 11 (canceled)

12. (currently amended) A method for regulating of increasing I-BAPP expression in a mammal ~~which comprises activating or inhibiting the Farnesoid X Receptor~~ comprising administering an effective amount of a non-steroidal Farnesoid X Receptor agonist to said mammal.

13. (currently amended) The method of claim 12, ~~which comprises binding an activating amount of chenodeoxycholic acid to the Farnesoid X Receptor where said Farnesoid X Receptor agonist is GW4064.~~

14. (canceled)

15. (currently amended) A method of regulating the bile transport system increasing bile acid transport from the intestinal lumen across the intestinal membrane in a mammal which comprises activating the Farnesoid X Receptor with a binding ligand administering an effective amount of a non-steroidal Farnesoid X Receptor agonist to said mammal.

16. (currently amended) The method of claim 15, wherein said FXR agonist is GW4064 the binding ligand is GW4064, chenodeoxycholic acid, lithocholic acid, deoxycholic acid, or a glycine or taurine conjugated conjugate derivative thereof.

17-19 (cancelled)

20. (currently amended) A method of lowering serum triglycerides treating in a mammal a disease which is affected by cholesterol, triglyceride, or bile acid levels

12, 13, 15, 16, 20, 21 pending

3

I 12, 13
II 15, 16
III 20
IV 21

broken up more
w/ various compounds

all methods which differ b/c ...
and use different compounds which vary ...

comprising administering to a mammal in need of such treatment ~~a therapeutically effective an effective serum triglyceride lowering amount of a non-steroidal agonist ligand for Farnesoid X Receptor.~~

21. (currently amended) A method of treating ~~atherosclerosis, gallstone disease, lipid disorders, obesity or a cardiovascular disorder in a mammal in need of such treatment, comprising administration of a therapeutically effective amount of a compound which was identified by the method of Claim 4 non-steroidal FXR agonist.~~

22-35 (canceled)